About
Eugenii Rabiner is a Reader in Molecular Neuroimaging at King’s College London’s Institute of Psychiatry, Department of Neuroimaging. He also serves as Executive Vice President and Head of Translational Applications at Invicro, and previously held leadership roles at Imanova Ltd. and the GSK Clinical Imaging Centre. His research focuses on molecular imaging techniques (PET/MRI) to investigate neurochemistry, neuroinflammation, and drug development.
Education: BSc Hons, MBChB from University of the Witwatersrand (1988–1990), Fellowship in Psychiatry (FCPsych SA, 1996). Postgraduate training included PET imaging at the MRC Cyclotron Unit (1997–2001), with collaborations at the University of Oxford’s Psychopharmacology Unit.
Research emphasizes optimizing imaging methods for drug development, particularly targeting neurotransmitter systems and neuroinflammation. Recent work includes quantifying neuroinflammation and extending neurotransmitter detection beyond dopamine. Collaborations span international institutions like Yale University and SUNY Stony Brook.
Notable projects include iMarkHD (Huntington’s disease imaging protocols) and studies on synaptic terminal density in schizophrenia. He has led grants on topics like PET radioligand characterization and multimodal imaging in neurodegenerative diseases.
